Table 1.

Clinical Trials Targeting RhoGTPase in Vascular Diseases.

	Trial	Drug
NCT03753269	Early Intracoronary Administration of Fasudil in the Primary PCI of ST-segment-Elevation Myocardial Infarction	Fasudil
NCT03404843	Red Blood Cell ATP Release and Vascular Function in Humans	Fasudil/Saline
NCT00120718	The Effect of Fasudil on Vascular Function in Humans	Fasudil
NCT00670202	Rho Kinase (ROCK) Inhibition in Carotid Atherosclerosis	Fasudil/placebo
NCT03391219	Combined Intravitreal Injection of Bevacizumab and Fasudil Versus Bevacizumab Alone for Macular Edema Secondary to Retinal Vein Occlusion in Previously Treated Patients	Avastin Avastin/fasudil
NCT00498615	A Rho-kinase Inhibitor (Fasudil) in the Treatment of Raynaud’s Phenomenon	Fasudil
NCT00560170	Vascular Effects of Ezetimibe/Simvastatin and Simvastatin on Atherosclerosis	Statin/ROCK biomarker
NCT01823081	Trimetazidine in Pulmonary Artery Hypertension	Trimetazidine/ROCK biomarker
NCT01732718	NCT01732718 Effect of Atorvastatin on Endothelial Dysfunction and Albuminuria in Sickle Cell Disease (ENDO)	Statin ROCK biomarker
NCT02754518	Demonstration of Reverse Remodeling Effects of Entresto (Valsartan/Sacubitril) Using Echocardiography Endocardial Surface Analysis	Entresto ROCK biomarker
NCT00839449	Eicosapentaenoic Acid Cerebral Vasospasm Therapy Study (EVAS)	ROCK biomarker
NCT01065753	Multi-faceted Evaluations Following Weight Reduction in Subjects With Metabolic Syndrome	Rho biomarker
NCT00115830	Rho Kinase in Patients With Atherosclerosis	ROCK biomarker
NCT01069042	Anti-Hypertensive Agent (ACEi) and Heart Function Improvement in Association With Rho Kinase Activity Changes in Human	ROCK biomarker

Additional more specific ROCK inhibitors being tested are 28 Asahi Kasei cerebral vasospasm approved (Japan and China), 165 Kowa glaucoma approved (Japan), diabetic retinopathy phase 2, 45 Kadmon psoriasis phase 2, idiopathic pulmonary fibrosis Phase I.